News
IDEAYA/Servier PKC drug aces uveal melanoma trial
Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
News
AI could spare bowel cancer patients from unneeded treatment
An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.
News
Data backs GSK's ovarian cancer blockbuster hopes
GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.
News
FDA hands another rejection to Replimune's melanoma therapy
Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
News
Roche places a $1bn bet on C4T degrader-antibody conjugates
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
